| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* To whom correspondence should be addressed. E-mail: gaoxu.changhai{at}gmail.com.
The receptor mechanism of testosterone-induced nongenomic
Ca2+ signaling in prostate cancer cells is
poorly understood. In this study, we investigated
androgens-induced increases in intracellular
Ca2+ in LNCaP human prostate cancer cells by
using fura-2 as a Ca2+ probe.
5'-dihydrotestosterone (DHT) produced fast and transient increases in intracellular Ca2+ in LNCaP cells in a concentration-dependent manner. These effects were
abolished by extracellular Ca2+ removal or
pretreatment with L-type Ca2+ channel
inhibitors (Nifedipine, Verapamil and Diltiazem).
Pretreatment with endoplasmic reticulum ryanodine receptor
blocker (procaine) or phospholipase C inhibitor (neomycin
sulfate) did not alter the DHT induced Ca2+
influx. Ca2+ increases could also be induced by
the impermeable testosterone conjugated to BSA. Neither
antagonist of intracellular androgen receptors (CPA) nor
protein synthesis inhibitor (cycloheximide) affects this
fast Ca2+ influx. Furthermore, the effect of
DHT was abolished in cells incubated with G protein
inhibitors (pertussis toxin) and a nonhydrolyzable analog
of GTP (GDP
S), but not cells incubated with the
tyrosine kinase inhibitor (genistein). The results
indicate that androgens induced an L-type calcium channel
dependent intracellular calcium increase in LNCaP prostate
cancer cells. The rapid responses triggered by DHT did not
appear to be mediated through classic intracellular
androgen receptors or the c-Src kinase-AR complex or the
sex hormone-binding globulin (SHBG). To our knowledge, we
report for the first time that androgens induce calcium
influx via a G protein-coupled receptor in LNCaP Prostate
Cancer Cells. These results might provide a new
explanation for progression of prostate cancer.
Key words: 5
-dihydrostestosterone
Ca2+
prostate cancer cells
G Protein-Coupled Receptor
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |